Singapore markets open in 1 hour 52 minutes

CStone Pharmaceuticals (2616.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
1.270-0.030 (-2.31%)
At close: 04:08PM HKT
Full screen
Previous close1.300
Open1.340
Bid1.270 x 0
Ask1.280 x 0
Day's range1.160 - 1.360
52-week range0.800 - 3.270
Volume4,306,000
Avg. volume2,789,072
Market cap1.62B
Beta (5Y monthly)0.17
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website

    CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the abstract containing the preliminary data from the first-in-human, global, multi-regional, phase 1a/1b study of CS5001 (ROR1 ADC) in patients with advanced solid tumors and lymphomas has been published on the website of the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. Additional up-to-date clin

  • PR Newswire

    CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today reported 2023 annual results and recent business updates.

  • PR Newswire

    CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer

    CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly®) in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment for unresectabl